Ildong Holdings Co., Ltd. (KRX:000230)

Market Cap	114.73B +65.7%
Revenue (ttm)	590.89B -6.9%
Net Income	10.93B -82.7%
EPS	967.00 -80.9%
Shares Out	11.29M
PE Ratio	13.32
Forward PE	n/a
Dividend	100.00 (1.00%)
Ex-Dividend Date	Mar 30, 2026

Volume	31,374
Average Volume	30,632
Open	10,100
Previous Close	10,060
Day's Range	9,910 - 10,200
52-Week Range	5,890 - 17,170
Beta	0.37
RSI	48.12
Earnings Date	May 13, 2026

About Ildong Holdings

Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer’s disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the research and manufacture of health foods and ingredients; and provides hyaluronic acid for use in drugs, medical devices, and cosmetics. In addition, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1941
• Employees: 72
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000230

Financial Performance

In 2025, Ildong Holdings's revenue was 590.89 billion, a decrease of -6.90% compared to the previous year's 634.65 billion. Earnings were 10.93 billion, a decrease of -82.67%.